ANIP (STOCKS)
ANI Pharmaceuticals, Inc.
$77.595000
-2.315000 (-2.90%)
Prev close: $79.910000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Nikhil Lalwani
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,743.49M
- Employees
- 897
- P/E (TTM)
- 49.01
- P/B (TTM)
- 3.55
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
7
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$2.04 | $1.79 | +0.2512 | +14.04% |
|
Jun 2025 (Q2)
|
$1.80 | $1.45 | +0.3516 | +24.28% |
|
Mar 2025 (Q1)
|
$1.70 | $1.41 | +0.2898 | +20.55% |
|
Dec 2024 (Q4)
|
$1.63 | $1.46 | +0.1663 | +11.36% |
Financial Statements
| Revenues | $826.88M |
| Benefits Costs and Expenses | $776.33M |
| Costs And Expenses | $754.93M |
| Operating Expenses | $754.93M |
| Selling, General, and Administrative Expenses | $304.67M |
| Depreciation and Amortization | $91.40M |
| Research and Development | $56.05M |
| Other Operating Expenses | $302.81M |
| Operating Income/Loss | $71.95M |
| Income/Loss From Continuing Operations After Tax | $40.57M |
| Income/Loss From Continuing Operations Before Tax | $50.55M |
| Income Tax Expense/Benefit | $9.98M |
| Interest And Dividend Income, Operating | $11.74M |
| Net Income/Loss | $40.57M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $40.57M |
| Net Income/Loss Available To Common Stockholders, Basic | $39.01M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $6.42M |
| Preferred Stock Dividends And Other Adjustments | $1.56M |
| Undistributed Earnings/Loss Allocated To Participating Securities, Basic | $4.87M |
| Basic Earnings Per Share | $1.71 |
| Diluted Earnings Per Share | $1.60 |
| Basic Average Shares | 59,558,000 |
| Diluted Average Shares | 61,490,000 |
| Assets | $1.41B |
| Current Assets | $698.40M |
| Inventory | $146.48M |
| Prepaid Expenses | $18.55M |
| Other Current Assets | $533.38M |
| Noncurrent Assets | $709.75M |
| Fixed Assets | $63.56M |
| Intangible Assets | $499.82M |
| Other Non-current Assets | $146.37M |
| Liabilities | $902.34M |
| Current Liabilities | $270.56M |
| Accounts Payable | $69.80M |
| Wages | $33.22M |
| Other Current Liabilities | $167.54M |
| Noncurrent Liabilities | $631.78M |
| Equity | $505.82M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $505.82M |
| Temporary Equity | $0.00 |
| Temporary Equity Attributable To Parent | $0.00 |
| Liabilities And Equity | $1.41B |
| Net Cash Flow From Operating Activities | $170.72M |
| Net Cash Flow From Operating Activities, Continuing | $170.72M |
| Net Cash Flow From Investing Activities | -$43.60M |
| Net Cash Flow From Investing Activities, Continuing | -$43.60M |
| Net Cash Flow From Financing Activities | -$10.22M |
| Net Cash Flow From Financing Activities, Continuing | -$10.22M |
| Exchange Gains/Losses | $725.00K |
| Net Cash Flow | $117.63M |
| Net Cash Flow, Continuing | $116.90M |
| Comprehensive Income/Loss | $38.02M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $38.02M |
| Other Comprehensive Income/Loss | -$2.56M |